Boston Scientific to end suit, pay $195m
Guidant allegedly hid defect in defibrillators
Boston Scientific Corp. will pay $195 million to settle a class-action suit against its Guidant division, ending a legal battle in which patients claimed Guidant Corp. knowingly hid defects in its implantable heart devices. (Full article: 446 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
